Oral MRT-2359
MRT-2359-001
Phase 2 small_molecule active
Quick answer
Oral MRT-2359 for NSCLC is a Phase 2 program (small_molecule) at Monte Rosa Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Monte Rosa Therapeutics
- Indication
- NSCLC
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active